NEW YORK (GenomeWeb News) – An array-based analysis by researchers from Australia and elsewhere has identified a gene that is often missing in ovarian cancers that become resistant to liposomal doxorubicin chemotherapy, hinting that it may serve as a marker for such acquired resistance.
Australia's National Health and Medical Research Council has awarded the University of Queensland about US$19.3 million to support it's cancer genome sequencing project aimed at characterizing pancreatic and ovarian cancers.
